Abstract Details

Title Real-World Cost and Utilization Analysis of Botulinum Toxin Agents in Blepharospasm: A National Retrospective Cohort Study

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 438

Objective To evaluate real-world costs, dosing, and wastage of incobotulinumtoxinA (INCO) and onabotulinumtoxinA (ONA) for blepharospasm treatment.

Background The IQVIA Health Plan Claims Database is the largest non-payer repository of commercial health claims in the US. It includes data from >100 million covered lives. Limitations of this retrospective analysis include but are not limited to non-interchangeability of toxins, limited data, as well as no analysis of discounts or other price reductions.

Design/Methods This analysis used three years (2018-2020) of data. Inclusion criteria were: outpatient claims with a Current Procedural Terminology (CPT) code of 64642; a primary ICD-10 diagnosis code of G24.5 (blepharospasm); and a J-code of J0585 (ONA) or J0588 (INCO). The primary outcome of the study was cost per claim for INCO and ONA. The cost per year analysis included data from patients diagnosed with blepharospasm and who received ≥2 injections of ONA or INCO for ≥12 months.

Results A total of 46,540 claims (40,661 ONA; 5,879 INCO) were included. Most claims were submitted by ophthalmologists (70.0%) and were for female patients (70.5%). The mean cost per claim was significantly higher for ONA than for INCO ($601 versus $404; p<0.001). The mean dose per claim was 48.0 units for ONA and 46.5 units for INCO (p<0.001). The mean wastage per claim was significantly higher for ONA than for INCO (55.0 units versus 32.1 units; p<0.001). The mean cost per patient per year was $1,765 for ONA and $976 for INCO (p<0.001).

Conclusions Significant cost savings for payers can be realized through the use of INCO for blepharospasm patients, which offers a lower acquisition cost and opportunities to minimize wastage. INCO and ONA were utilized with dosing at a 0.97 to 1.0 ratio, which is consistent with active comparator studies that demonstrate similar safety and efficacy at comparable doses.

Authors/Disclosures
Rashid Kazerooni PRESENTER	Rashid Kazerooni has received personal compensation for serving as an employee of Merz Therapeutics.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��